Bristol Myers Squibb (CELG-RI) Inventory (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Inventory of $2.7 billion for Q2 2026, little changed year-over-year from $2.7 billion in Q2 2025, and down 0.69% quarter-over-quarter from $2.8 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Inventory (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Inventory for 18 consecutive years, with $2.7 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Inventory changed 0.0% year-over-year to $2.7 billion; the TTM figure through Jun 2026 stood at $2.7 billion (changed 0.0% YoY), while the FY2025 annual figure was $2.7 billion, up 5.2% from the prior year.
- Inventory fell to $2.7 billion in Q2 2026 per CELG-RI's latest filing, from $2.8 billion in the prior quarter.
- Across five years, Inventory topped out at $3.3 billion in Q3 2024 and bottomed at $2.1 billion in Q3 2022.
- Historically, Inventory has averaged $2.6 billion across 5 years, with a median of $2.7 billion in 2023.
- Annual changes were most pronounced in 2024 — Inventory soared 36.78% — and 2025, when it dropped 17.23%.
- Bristol Myers Squibb's Inventory stood at $2.3 billion in 2022, then gained by 13.81% to $2.7 billion in 2023, then slipped by 3.94% to $2.6 billion in 2024, then rose by 5.2% to $2.7 billion in 2025, then increased by 1.75% to $2.7 billion in 2026.
- Business Quant data shows CELG-RI's Inventory at $2.7 billion in Q2 2026, $2.8 billion in Q1 2026, and $2.7 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.77 Bn | 633.01 Bn | 17.26 Bn | 15.14 Bn |
| 2 | AbbVie | 470.28 Bn | 463.71 Bn | 12.70 Bn | 5.13 Bn |
| 3 | Merck | 377.51 Bn | 370.37 Bn | 12.21 Bn | 6.21 Bn |
| 4 | Novartis Ag | 302.99 Bn | 295.30 Bn | 11.24 Bn | 6.22 Bn |
| 5 | Astrazeneca | 258.01 Bn | 253.11 Bn | 12.86 Bn | 6.93 Bn |
| 6 | Amgen | 236.60 Bn | 222.61 Bn | 7.24 Bn | 6.22 Bn |
| 7 | Gilead Sciences | 183.35 Bn | 180.17 Bn | 6.22 Bn | 1.95 Bn |
| 8 | Pfizer | 160.34 Bn | 148.64 Bn | 10.94 Bn | 9.95 Bn |
| 9 | Gsk | 106.10 Bn | 101.93 Bn | 8.24 Bn | 8.43 Bn |
| 10 | Bristol Myers Squibb | 208.28 Mn | -10.86 Bn | 9.25 Bn | 2.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.74 Bn |
| Mar 31, 2026 | 2.76 Bn |
| Dec 31, 2025 | 2.69 Bn |
| Sep 30, 2025 | 2.76 Bn |
| Jun 30, 2025 | 2.74 Bn |
| Mar 31, 2025 | 2.67 Bn |
| Dec 31, 2024 | 2.56 Bn |
| Sep 30, 2024 | 3.33 Bn |
| Jun 30, 2024 | 3.08 Bn |
| Mar 31, 2024 | 2.99 Bn |
| Dec 31, 2023 | 2.66 Bn |
| Sep 30, 2023 | 2.44 Bn |
| Jun 30, 2023 | 2.36 Bn |
| Mar 31, 2023 | 2.61 Bn |
| Dec 31, 2022 | 2.34 Bn |
| Sep 30, 2022 | 2.07 Bn |
| Jun 30, 2022 | 2.14 Bn |
| Mar 31, 2022 | 2.10 Bn |
| Dec 31, 2021 | 2.10 Bn |
| Sep 30, 2021 | 2.16 Bn |